Unity Biotechnology, Inc.
UBX · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.02 | -0.04 | 0.12 |
| FCF Yield | -36.23% | -35.94% | -20.97% | -20.50% |
| EV / EBITDA | -4.79 | -3.93 | -5.84 | -7.20 |
| Quality | ||||
| ROIC | -27.37% | -20.38% | -14.41% | -14.44% |
| Gross Margin | 0.00% | 50.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.70 | 0.80 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,099,070.14% | 1,099,070.14% | -27.64% | -27.64% |
| Free Cash Flow Growth | -7.65% | -13.71% | -13.29% | 11.56% |
| Safety | ||||
| Net Debt / EBITDA | -2.18 | -1.94 | -1.88 | -2.78 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -890.39 | -125.72 | -751.67 | -592.94 |